Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288526 | PMC |
| http://dx.doi.org/10.18240/ijo.2018.12.27 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Empagliflozin and the Risk of Retinopathy in Patients With Type 2 Diabetes.
JAMA Ophthalmol
January 2025
Department of Medicine, Division of Pharmacoepidemiology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Article Synopsis
- Empagliflozin may reduce the risk of diabetic retinopathy (DR) by preventing the loss of retinal pericytes, but its effectiveness compared to DPP4 inhibitors in patients with type 2 diabetes (T2D) is not well established.
- A study was conducted using U.S. insurance claims data from 2014 to 2019, focusing on adults with T2D who were newly prescribed either empagliflozin or a DPP4 inhibitor, and looking at the incidence of nonproliferative DR and its progression.
- Results showed that among matched patient pairs, empagliflozin's impact on the rates of incident DR and progression was analyzed, with significant data collected over an average
Curcuma-Based Nutritional Supplements and Risk of Age-Related Macular Degeneration.
JAMA Ophthalmol
December 2024
Department of Ophthalmology, Byers Eye Institute, Horngren Family Vitreoretinal Center, Stanford University School of Medicine, Palo Alto, California.
Importance: Curcuma-based nutritional supplements (CBNS) are natural anti-inflammatory and antioxidant agents that may confer benefits against age-related macular degeneration (AMD).
Objective: To examine the association between the use of CBNS and the risk of development or progression of AMD.
Design, Setting, And Participants: This was a retrospective cohort study with data collection in June of 2024.
Tissue Plasminogen Activator or Perfluoropropane for Submacular Hemorrhage in Age-Related Macular Degeneration: A Factorial Randomized Clinical Trial.
JAMA Ophthalmol
December 2024
King's Ophthalmology Research Unit, Ophthalmology Department, King's College Hospital, London, United Kingdom.
Importance: Evidence is limited to support therapies to treat submacular hemorrhage (SMH) secondary to neovascular age-related macular degeneration (AMD) as an adjunct to anti-vascular endothelial growth factor therapy (anti-VEGF).
Objective: To determine if intravitreal tissue plasminogen activator (TPA) or gas improves visual acuity or promotes resolution of SMH secondary to neovascular AMD in eyes treated with ranibizumab.
Design, Setting, And Participants: This was a double-masked, sham-controlled, factorial randomized clinical trial and feasibility study that recruited participants from June 2014 to March 2019, with 12 months' follow-up.
[Use of shorter injection cannulas prevents complications in intravitreal drug administration].
Ophthalmologie
September 2024
Augenzentrum Lister Platz, Lister Platz 3, 30163, Hannover, Deutschland.
Endophthalmitis Rates and Types of Treatments After Intraocular Procedures.
JAMA Ophthalmol
September 2024
Vickie and Jack Farber Vision Research Center at Wills Eye, Wills Eye Hospital, Philadelphia, Pennsylvania.
Importance: Long-term trend analyses of overall endophthalmitis rates and treatment patterns are scarce. It is also unknown if the deviation from the recommendations of the Endophthalmitis Vitrectomy Study toward decreased utilization of vitrectomy is associated with different vision outcomes.
Objective: To determine whether the rate of endophthalmitis after intraocular procedures or the primary treatment (prompt vitrectomy vs tap and inject) for endophthalmitis has changed over the past 20 years.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!